Compare Synchrony Financial (SYF) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Synchrony FinancialTrade

Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Synchrony Financial vs Zimmer Biomet Holdings Inc — how do they compare? Synchrony Financial trades at $71.7 (market cap $24.69B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Synchrony Financial is the larger of the two by market cap, and Synchrony Financial pays the higher dividend (1.63%). Which is the better fit depends on your goals.

	SYF	ZBH
Market Cap	$24.69B	$17.36B
Sector	Financials	Health
52-Week High	$88.47	$107.71
52-Week Low	$63.78	$79.58
Dividend Yield	1.63%	1.07%
Enterprise Value	—	$24.40B

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

SYF

Consumers keep spending frequently despite inflation, boosting Synchrony's Q2 purchase volume 8%.PYMNTS · 6 hours agoBullish Synchrony Financial declares $0.34 quarterly dividend per common share, payable August 17, 2026.PRNewsWire · 15 hours agoNeutral View details →

ZBH

View details →

About Synchrony Financial

Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.